The pharma landscape has an established distribution pipeline: manufacturer partners with wholesaler, wholesaler navigates regional complexities through sales to pharmacy chains. In practice, however, this seemingly straightforward approach often complicates control for the manufacturer. This has led to a search for alternative distribution models, where manufacturers can take charge of supply channels to increase efficiency and promote flexibility without affecting patient needs.

Facing recent FTC scrutiny over its $16.5 billion merger with Novo Holdings, the CDMO signs up to manufacture adeno-associated viral vector-based therapies for cancer.

The drugmaker had previously paused the trial in 2021 following a patient death in its phase 1b study.

Upholding rigorous quality standards is not only a regulatory imperative but also vital for ensuring the efficacy and safety of pharmaceutical products. And as many pharma manufacturers have discovered, enhanced quality processes can also unlock significant performance improvements.